BI Asset Management Fondsmaeglerselskab A S Sells 20,444 Shares of Tenet Healthcare Corporation $THC

BI Asset Management Fondsmaeglerselskab A S cut its holdings in shares of Tenet Healthcare Corporation (NYSE:THC) by 19.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 83,462 shares of the company’s stock after selling 20,444 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Tenet Healthcare were worth $15,750,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Triumph Capital Management acquired a new stake in Tenet Healthcare during the third quarter worth approximately $25,000. Activest Wealth Management acquired a new position in Tenet Healthcare in the 4th quarter valued at $26,000. Elyxium Wealth LLC bought a new stake in shares of Tenet Healthcare during the 4th quarter valued at $29,000. Canada Pension Plan Investment Board acquired a new stake in shares of Tenet Healthcare during the 2nd quarter worth $35,000. Finally, Meeder Asset Management Inc. increased its position in shares of Tenet Healthcare by 146.2% in the fourth quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock worth $38,000 after purchasing an additional 114 shares during the period. 95.44% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Tenet Healthcare news, Director J Robert Kerrey sold 5,638 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $174.52, for a total transaction of $983,943.76. Following the sale, the director owned 16,804 shares of the company’s stock, valued at approximately $2,932,634.08. The trade was a 25.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Nadja West sold 3,000 shares of the company’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total transaction of $532,050.00. Following the transaction, the director owned 24,805 shares of the company’s stock, valued at $4,399,166.75. This trade represents a 10.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.97% of the company’s stock.

Tenet Healthcare Stock Up 0.0%

Shares of NYSE THC opened at $172.63 on Friday. The company has a market cap of $14.87 billion, a price-to-earnings ratio of 8.98, a PEG ratio of 1.42 and a beta of 1.28. The company has a current ratio of 1.36, a quick ratio of 1.30 and a debt-to-equity ratio of 1.96. Tenet Healthcare Corporation has a 12 month low of $146.60 and a 12 month high of $247.21. The stock has a 50-day moving average price of $182.44 and a two-hundred day moving average price of $198.55.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings results on Thursday, April 30th. The company reported $4.82 earnings per share for the quarter, beating analysts’ consensus estimates of $4.21 by $0.61. The company had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.39 billion. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period last year, the company posted $4.36 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. As a group, analysts forecast that Tenet Healthcare Corporation will post 17.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on THC shares. Wells Fargo & Company reduced their price objective on shares of Tenet Healthcare from $265.00 to $213.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Stephens dropped their target price on shares of Tenet Healthcare from $275.00 to $260.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. Barclays reduced their price target on shares of Tenet Healthcare from $257.00 to $238.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 5th. Robert W. Baird decreased their price objective on shares of Tenet Healthcare from $245.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 5th. Finally, Guggenheim cut their target price on Tenet Healthcare from $283.00 to $252.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Eighteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $244.16.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.